The Paddingtons and David Franklin (scientist)

The Paddingtons are an English indie rock band from Hull. Between April 2005 and 9 November 2006, they played over 150 live shows, including venues such as Trent Park Golf Club, The Square, Harlow; Jersey Live; Summercase; The Underground, Stoke-on-Trent; T in the Park and at the Reading and Leeds Festivals.

Contents 1 Career 2 Discography 2.1 Studio albums 2.2 Compilation albums 2.3 Singles 2.4 EPs 3 See also 4 References 5 External links

Career

Composed of Tom Atkin (vocalist), Stuee Bevan (guitarist) (originally Martin Hines), Josh Hubbard (guitarist); and brothers Lloyd (bassist) and Grant Dobbs (drummer), they were signed by Alan McGee to his Poptones record label. They originally made their name touring in and around the Hull area, at such venues as the Welly Club, the New Adelphi Club, and the Railway pub in Cottingham. Favoured by ex-Libertines frontman Pete Doherty, they toured with Babyshambles in 2005. Their debut album, First Comes First, was produced by Owen Morris, producer of Oasis' Definitely Maybe.

In November 2006, they headed out on a small scale national tour to road test new material. They appeared alongside The Cribs at the Birmingham Academy. The Paddingtons have also appeared with Dirty Pretty Things at "The Forum" in May, and again at The Spice Festival at the Hackney Empire in July 2007. On a holiday in Taipei, Carl Barat of Dirty Pretty Things broke his collarbone, so they recruited the help of Hubbard to play guitar while Barat's injury healed.

In December 2007, they appeared alongside The Neat and The View at Hull City Hall, as part of the Love Music Hate Racism campaign. During the same month they also played a free gig on Christmas Eve to raise money to refurbish the toilets in the New Adelphi Club. Their live sets have included a cover version of The Clash's song, "Janie Jones".

The band's second album, No Mundane Options, was released on 3 November 2008. The first single from the album, "Stand Down", was released on the Mama Bear Records label, on 4 August 2008.

In December 2009, the band announced plans to release a new EP "The Lady Boy Tapes", which was released the following year. Discography Studio albums 2005 - First Comes First 2008 - No Mundane Options Compilation albums 2004 - Bring Your Own Poison - The Rhythm Factory Sessions - (contributed an early version of the future album track - "Tommy's Disease"). 2006 - Back To The Bus Singles 2004 - "21" (UK No. 47) 2005 - "Panic Attack" (UK No. 25) 2005 - "50 to a Pound" (UK No. 32) 2005 - "Sorry" (UK No. 41) 2008 - "Stand Down" 2008 - "What's The Point in Anything New" EPs 2010 - "The Lady Boy Tapes" See also Bands and musicians from Yorkshire and North East England List of British punk bands List of indie rock musicians List of Mercury Records artists

David Franklin (scientist) and The Paddingtons

David Franklin is an American microbiologist and former fellow of Harvard Medical School who while employed by Parke-Davis filed the 1996 whistleblower lawsuit exposing their illegal promotion of Neurontin (gabapentin) for off-label uses. Franklin's suit, filed on behalf of the citizens of the United States under the qui tam provisions of US federal and state law, uncovered illegal pharmaceutical industry practices and created new legal precedent that resulted in a cascade of criminal convictions and civil and criminal penalties against Pfizer and several other pharmaceutical companies totalling more than $7 billion. Civil cases also followed Franklin v. Parke-Davis. Insurance companies, led by Kaiser Permanente, sued Pfizer for fraud and violation of the federal Racketeer Influenced and Corrupt Organizations Act; the Kaiser case settled in April 2014 after Pfizer's appeal at the US Supreme Court was rejected. Franklin v. Pfizer also spawned more than a thousand wrongful death (suicide) suits associated with use of Neurontin. Numerous books have addressed the social, economic and healthcare implications of Dr. Franklin's stance and actions. The settlement was the first off-label promotion settlement under the False Claims Act.:194 Franklin v. Parke-Davis case Main article: Franklin v. Parke-Davis

Franklin's suit, filed under the False Claims Act, claimed that Parke-Davis (since acquired by Pfizer) had used fraudulent scientific evidence supported by "tens of thousands of payments" to doctors for "consultations" and "studies" to encourage them to prescribe the drug for conditions including migraine, bipolar disorder and attention deficit disorder, even though it was approved for use only as adjunctive treatment in patients with partial seizures and postherpetic neuralgia. Prescribing a drug for such off-label use was not itself illegal, but promoting such use was prohibited by the U.S. Food and Drug Administration and federal law.

The case revealed that the company marketed the drug for these illnesses while withholding evidence that the drug was not effective for these illnesses. After initially denying wrongdoing, Pfizer pleaded guilty on 13 May 2004 to criminal violation of the Federal Food, Drug, and Cosmetic Act and paid a criminal fine of $240 million and $152m to state and federal healthcare programmes. Under the False Claims Act, Dr Franklin received $24.6m as part of the settlement agreement.

Franklin v. Parke-Davis opened a unique window into pharmaceutical industry practices through UCSF's archiving and study of documents obtained by Franklin’s attorney Thomas Greene. The case was unique in a number of ways: it was the largest settlement obtained for U.S. taxpayers in a case not joined by the Department of Justice, it established a new standard of accountability for pharmaceutical industry marketing practices, it broadened the use of the False Claims Act to include fraudulent marketing claims (not just financial fraud) as criminal violations of federal and state law, it revealed the involvement, complicity and active participation in fraud by many renowned physicians, and it demonstrated that the medical literature which is the foundation for medical practice (particularly off-label prescribing by physicians) has been deeply adulterated by the pharmaceutical industry and its paid clinical consultants.
199+255 198 200 201